PTGS2 and osteoarthritis: Most selective COX-2 inhibitors have been retired because of increased cardiovascular events; celecoxib, on the contrary, maintained its approval after a further safety investigation which did not revealed increased cardiovascular events compared to naproxen or ibuprofen [34] and it is currently indicated for a number of diseases including osteoarthritis, rheumatoid arthritis and juvenile arthritis.